Xtant Medical Holdings, Inc. (XTNT)
NYSEAMERICAN: XTNT · Real-Time Price · USD
0.5600
-0.0130 (-2.27%)
Aug 1, 2025, 4:00 PM - Market closed
Xtant Medical Holdings Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Xtant Medical Holdings.
Price Target: $0.00 (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Xtant Medical Holdings.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
BTIG | BTIG | Strong Buy Maintains $2 → $3 | Strong Buy | Maintains | $2 → $3 | +435.71% | May 16, 2024 |
BTIG | BTIG | Strong Buy Initiates $2 | Strong Buy | Initiates | $2 | +257.14% | Dec 5, 2023 |
Craig-Hallum | Craig-Hallum | Strong Buy Maintains $1 → $1.2 | Strong Buy | Maintains | $1 → $1.2 | +114.29% | Jul 11, 2023 |
Craig-Hallum | Craig-Hallum | Strong Buy Initiates $1 | Strong Buy | Initiates | $1 | +78.57% | Apr 26, 2023 |
Financial Forecast
Revenue This Year
132.14M
from 117.27M
Increased by 12.68%
Revenue Next Year
139.28M
from 132.14M
Increased by 5.40%
EPS This Year
-0.04
from -0.12
EPS Next Year
-0.02
from -0.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 |
---|---|---|---|
High | 136.2M | 143.6M | 155.6M |
Avg | 132.1M | 139.3M | 151.2M |
Low | 126.8M | 133.6M | 145.2M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | 16.1% | 8.7% | 11.7% |
Avg | 12.7% | 5.4% | 8.5% |
Low | 8.1% | 1.1% | 4.3% |
EPS Forecast
EPS | 2025 | 2026 |
---|---|---|
High | -0.02 | - |
Avg | -0.04 | -0.02 |
Low | -0.05 | -0.03 |
EPS Growth
EPS Growth | 2025 | 2026 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.